2.1 In vitro antioxidant effect
The extract from C. zizanoides leaves exhibited a DPPH free radical scavenging activity of 94.39% at a concentration of 200 lg/mL, whereas the leaf extract and ascorbic acid demonstrated activities of 89.10% and 89.10%, respectively (Figure 1). The IC50 values for the leaves extract and ascorbic acid were 257.23µg/ml and 7.8µg/ml, respectively. The results suggest that the leaf extract exhibited a modest level of antioxidant activity in comparison to the control group, which was treated with ascorbic acid.
2.2 Analgesic test
When given orally at a dosage of 500 mg/kg body weight, the extract resulted in a 58.8% decrease in writhing in mice. In comparison, the conventional medicine diclofenac sodium exhibited a 91.11% inhibition at a dosage of 10 mg/kg body weight. (Table 1).
2.3 Antibacterial test
C. zizanioides extract exhibited antibacterial activity against both gram-positive and gram-negative bacteria. The zones of inhibition for C. zizanioides were smaller than those of Ciprofloxacin, a broad-spectrum antibiotic used as a control, for all tested bacteria. However, the extract created an inhibition zone 30 ± 4.39 mm, 14 ± 4.39 mm, 8 ± 4.39 mm against Staphylococcus aureus, Vibrio mimicus, Bacillus megaterium against gram positive bacteria. It also demonstrated activity against other gram-negative bacteria with a zone of inhibition 22 ± 1.93 mm, 16 ± 1.93 mm, 15 ± 1.93 mm against Escherichia coli, Salmonella typhi, Salmonella paratyphi bacteria (Figure 2). These findings suggest that C. zizanioides extract possesses potential antibacterial properties, although further research is needed to determine the minimum inhibitory concentration (MIC) and identify the specific compounds responsible for this activity.
2.4 Molecular docking study
In our investigation, we employed Glide docking to achieve precise docking, scoring, and prediction of ligand binding modalities to receptors (Table 2). The compound 9,19-Cyclolanostan-3-ol acetate (3β) demonstrated strong binding with the receptors 4GQR, 5NN5, and 4GQQ compared to other ligands, indicating superior antidiabetic activity with 5NN5 and 4GQR (Figure 3), and enhanced antibacterial activity with 4GQQ (Figure 4). The human pancreatic α-amylase (RCSB ID: 4GQR), crucial for starch hydrolysis, is a major therapeutic target for type II diabetes. Additionally, 9,19-Cyclolanostan-3-ol acetate (3β) showed notable binding affinity with glutathione peroxidase (RCSB ID: 1GP1), human erythrocyte catalase (RCSB ID: 1QQW), and human superoxide dismutase (RCSB ID: 2C9V), indicating significant potential for antioxidant activity (Figure 5). Phytol, an acyclic diterpene alcohol and a chlorophyll constituent, also exhibited strong binding to Human Cyclooxygenase-2 (RCSB ID: 5F19), a protein involved in inflammation, suggesting its potential for analgesic effects (Figure 6). Docking of 9,19-Cyclolanostan-3-ol acetate (3β) against the proteins 5NN5, 4GQR, 4GQQ, 1QQW, 2C9V, and 1GP1 resulted in docking scores of -9.6820, -10.2851, -11.994, -11.4604, -9.8821, and -11.2322 kcal/mol, respectively and Phytol, while docking with the protein 5F19, achieved a docking score of -9.1677 kcal/mol, suggesting its potential for analgesic effects. Molecular docking studies showed that lower (more negative) docking scores reflect stronger binding affinities, indicating a higher potential for biological activity. Additionally, stronger binding usually correlated with greater in vivo potency, as the compound was more likely to effectively inhibit or modulate the target protein.
9,19-Cyclolanostan-3-ol acetate (3β) formed specific interactions with various proteins. With 5NN5, it established one alkyl bond with ILE174 (5.40 Å) and two hydrogen bonds with ASN148 (2.97 Å) and ASP95 (3.44 Å). In complex with 4GQR, 3β created three alkyl bonds with MET278 (5.45 Å), TYR319 (4.73 Å), and TYR323 (4.66 Å), one pi-alkyl bond with TYR276 (2.84 Å), and one hydrogen bond with TYR323 (3.60 Å). The 4GQQ complex included two hydrogen bonds with ARG195 (2.76 Å) and ARG337 (3.03 Å), one alkyl bond with LEU162 (4.13 Å), and five pi-alkyl bonds with HIS15 (4.84 Å), PHE17 (5.05 Å), TRP58 (5.17 Å), TYR62 (5.01 Å), and HIS201 (4.84 Å). Interaction with 2C9V involved two alkyl bonds with CYS111 (3.58 Å) and ILE113 (4.93 Å). The 1QQW complex displayed six alkyl bonds with ARG127 (5.12 Å, 4.90 Å), LYS177 (4.88 Å), ALA251 (3.38 Å), VAL182 (4.66 Å), and VAL247 (4.98 Å), two hydrogen bonds with GLY118 (3.31 Å) and LYS177 (3.26 Å), and one pi-alkyl bond with HIS466 (4.36 Å). Lastly, in the 1GP1 complex, 3β formed six alkyl bonds with ALA21 (4.45 Å), LEU89 (4.48 Å), PRO103 (5.38 Å), LYS93 (5.42 Å), LEU20 (4.77 Å), and LEU107 (5.12 Å), and one hydrogen bond with ASN90 (3.04 Å). Phytol, when bound to 5F19, formed six pi-alkyl bonds with PHE205 (4.96 Å), PHE209 (5.21 Å), PHE381 (4.99 Å), TYR385 (4.40 Å), TRP387 (5.12 Å), and PHE518 (5.15 Å), along with four alkyl bonds with VAL349 (4.43 Å), LEU384 (5.15 Å), LEU352 (4.07 Å), and LEU534 (3.77 Å).
2.5 ADMET study
A comprehensive assessment of the pharmacokinetic properties of the substances—including toxicity, excretion, metabolism, distribution, and absorption—was conducted using the admetSAR web server (Table 3). This server employs cut-off scores to evaluate these attributes, and all selected ligands have a relative molar mass of less than 500 Daltons. Human intestinal absorption data, which are crucial for initial ligand evaluation, indicates all compounds show excellent human intestinal absorption, with values near or at 1.0000. This suggests that these compounds are likely to be well-absorbed when administered orally11. Additionally, the ability of these compounds to cross the blood-brain barrier is significant for maintaining brain homeostasis12. The ligands shown favorable outcomes with regards to their capacity to pass across the blood-brain barrier, inhibition of P-glycoprotein which is favorable for avoiding drug-drug interactions mediated by P-glycoprotein, and be absorbed by the human intestines.
Further analysis of cancer-causing potential and toxicity revealed that none of the compounds are expected to have adverse effects, though Neophytadiene(0.4862) was noted for potential carcinogenicity. AMES toxicity test, with values close to 0.9, indicating a low likelihood of mutagenicity and, therefore, low genotoxic risk. The evaluation of hERG inhibition, critical for generating cardiac action potentials, showed that lack of strong hERG inhibition across all compounds suggests a low risk of inducing cardiac arrhythmias, suggesting that all are suitable for further laboratory testing.
Drug-likeness was assessed using the Lipinski Rule of Five criteria via the pkCSM server (Table 4). Although some drugs, particularly those for cancer treatment, may not meet all criteria, compounds should preferably possess a molecular weight that is lower than 500 Da, ≤5 hydrogen bond donors, ≤10 hydrogen bond acceptors, and a logarithm of the partition coefficient (logP) below 5. Though, all the compounds meet the molecular weight, hydrogen bond donor, and acceptor criteria of the Lipinski Rule of Five, their high AlogP values suggest that they may face challenges with solubility and, consequently, oral bioavailability. The AlogP values, indicative of lipophilicity, vary significantly across the compounds, ranging from 5.7489 (9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)) to 8.8196 (.gamma.-Sitosterol). Notably, all compounds have AlogP values exceeding the preferred maximum of 5, suggesting that while these high values indicate favorable properties for crossing biological membranes, the compounds' poor solubility, and potential for low bioavailability present significant challenges due to their high lipophilicity, which might influence their absorption and distribution properties.
The ADMET and Drug-likeness analysis showed that these compounds had excellent intestinal absorption, favorable blood-brain barrier permeability, and low toxicity. However, their high AlogP values suggested poor solubility and reduced oral bioavailability, which might limit their effectiveness as oral drugs. Finally, by balancing lipophilicity with improved solubility and bioavailability is crucial for their development as viable therapeutic agents.
2.6 PASS Prediction
The PASS algorithm accurately predicted biological activities with 90% accuracy based on analyzing structure-activity relationships (Table 5). PASS (Prediction of Activity Spectra for Substances) predictions use the terms Pa and Pi to describe the likelihood that a compound will display a certain biological activity. The Pa, or Probability of Activity, indicates how likely the compound will show the predicted activity, with values ranging from 0 to 1. A higher Pa value suggests a stronger chance that the compound will have the desired effect. Conversely, Pi, or Probability of Inactivity, represents the probability that the compound will not exhibit the specified activity. Pi also ranges from 0 to 1, and a higher value implies a greater likelihood that the compound lacks the predicted activity. The relationship between Pa and Pi helps assess confidence in the prediction, with a higher Pa typically signaling a greater likelihood of the compound being active. According to the PASS prediction, Phytol emerges as a standout compound with high predicted activity in antioxidant (Pa of 0.475 and Pi of 0.008) and antibacterial (Pa of 0.417 and Pi of 0.026) areas, while 9,12,15-Octadecatrienoic acid, methyl ester and Neophytadiene show strong potential in antidiabetic (Pa of 0.400 and Pi of 0.013) and antioxidant areas, respectively. 13-Docosenamide has the highest probability of being an analgesic stimulant with a Pa of 0.326 and a Pi of 0.020, while other compounds exhibit a range of activities, with varying degrees of potential across different biological effects.
2.6 GC-MS screening
The GC/MS analysis of the extract has identified 63 compounds based on their retention durations, and their structures have been validated using the NIST Library of chemicals (Table S1) (Figure 7). The chemicals that have been discovered are shown together with their retention duration, area percentage, molecular weight, and molecular formula (Table 6). According to Table S1, there were thirteen esters, three hydrocarbons, two sesquiterpenes, and five alcohol. The chemical found in the extract is 9,19-Cyclolanostan-3-ol, acetate, (3.beta.), having a peak area of 8.8%. followed by 13-Docosenamide, (Z)- (8.35%), 1,4-Benzenedicarboxylic acid, bis(2- ethylhexyl) ester (7.01%), .gamma.-Sitosterol (5.20%), Neodiosgenin (3.beta.,25S) acetate (4.8%), 15.alpha.-Hydroxyculmorin (4.03%) etc. are the majorly occurring compounds.